Critical Care Nutrition: Systematic Reviews May 2021

7.1 Combination Parenteral Nutrition and Enteral Nutrition

Question: Does the use of parenteral nutrition in combination with enteral nutrition result in better outcomes in the critically ill adult patient?

Summary of evidence: 12 randomized controlled trials were reviewed and meta-analysed¹⁻¹².

Fifty percent (6/12) reported adequate generation of the random sequence, 46 % (5/12) of the RCTs reported adequate allocation sequence concealment and eight % (1/12) of the included RCTs reported adequate blinding of the outcome assessors. Nine trials compared EN+PN (an early combined enteral and parenteral nutrition) to EN, three trials compared SPN (where EN is supplemented by PN after some period, if full EN is impossible, or fails to reach nutrition targets) to EN. Five trials were published before 2000 and 7 trials after 2000. Seven trials included patients without nutritional risk assessment and five trials included patients evaluated to be at nutritional risk.

A priori defined subgroup analyses were:

1. Trials of patients receiving EN+PN or SPN vs. EN alone compared to trials of patients receiving SPN vs. EN alone, as these are different strategies regarding the timing of PN may have a different clinical effect.

2. Trials published until 2000 compared to trials published later than 2000, as "major relevant changes were implemented after new scientific data became available around the start of the new millennium"

3. Trials recruiting patients at increased risk for malnutrition or nutrition risk compared to trials that included heterogenous groups of patients without consideration of nutrition status as these different patient populations may respond differently to nutritional therapy.

Trials, where intravenous nutrients were given in both groups (Casaer and Chiarelli) were excluded in sensitivity analyses.

Mortality: All 12 studies reported on mortality (Figure 1). Data was collated to 30-day mortality. On average, no significant effect of any combination of EN with PN on "mortality within 30 days" was observed (Risk Ratio [RR] 1.0, 95% confidence intervals [CI], 0.79 to 1.28 p = 0.99) with low to moderate statistical heterogeneity ($I^2 = 30\%$). A subgroup analysis in a single trial did demonstrate a tendency towards lower mortality in nutritionally high-risk patients when EN+PN was provided (p = 0.19 in patients with NUTRIC Score \geq 5 and Body Mass Index <25 kg/m²). In the sensitivity analysis, after excluding the Chiarelli and Casaer trials, the resultant effect was similar: RR 1.00., 95% CI, 0.70 to 1.44, p=1.00).

In our subgroup analyses, no difference in treatment effect was observed in RCTs using EN+PN vs. those using SPN (test for subgroup differences p = 0.72, Figure 1), in RCTs published until 2000 vs. those published after 2000 (test for subgroup differences, p = 0.18, Figure 2), nor in trials patients with or without a baseline nutrition risk assessment (test for subgroup differences, p = 0.28, Figure 3).

Infections: Seven trials reported on the outcome "infectious complications", but time window for its assessment as well as the definition of infection was too heterogeneous to perform meta-analysis. Differences between treatment groups were observed in three trials. An older RCT performed by

Chiarelli et al. observed different rates of pneumonia (50% infections in the EN+PN group [6/12] and 25% in the EN group [3/12]) as defined by positive bronchial aspirate and x-ray of the chest. Casaer et al. observed statistically significant more infections in the EN+PN group (p=0.008), which included airway, bloodstream, wound and urinary tract infections. Heidegger et al. reported a lower risk of nosocomial infection from days 9-18 in the SPN group in comparison to EN alone (hazard ratio 0.65, 95% CI 0.43–0.97; p=0.0338), and the SPN group had a lower mean number of nosocomial infections per patient (hazard ratio-0.42 CI –0.79 to –0.05; p=0.0248). With the data obtained from the authors for days 4 – 28, no differences between groups were found. No statistically significant differences regarding infection rates were observed in the other four trials that reported this outcome.

Hospital LOS: When the data from the 8 studies that reported hospital length of stay as a mean \pm standard deviation were aggregated, on average, no significant effect of any combination of EN with PN on hospital LOS was observed (mean difference [MD]-1.44, CI -5.59 to 2.71, p = 0.50) with substantial statistical heterogeneity (I² = 88%) was observed (Figure 4). In the sensitivity analysis, after excluding the Chiarelli and Casaer trials, the resultant effect was greater: MD -3.00, 95% CI, -6.40 to 0.40, p=0.08.

There was no difference in the treatment effect in RCTs using EN+PN vs. those using SPN, RCTs published until 2000 vs. those published after 2000, nor in RCTs patients with or without a baseline nutrition risk assessment (test for subgroup differences, p = 0.88 [Figure 4], p = 0.97 [Figure 5] and p = 0.99 [Figure 6]).

ICU LOS: Seven studies reported this outcome (Figure 7). On average, no significant effect of any combination of EN with PN on ICU LOS was observed (MD -0.15, CI -2.05 to 1.75, p = 0.88) with substantial statistical heterogeneity (I2 = 88%). Sensitivity analysis showed no difference when the trials by Casaer et al. and Chiarelli et al. were excluded (MD -0.81, 95% CI, -2.42 to 0.80, p=0.32).

There was no difference in the treatment effect in RCTs using EN+PN vs. those using SPN, RCTs published until 2000 vs. those published after 2000, nor in RCTs patients with or without a baseline nutrition risk assessment (test for subgroup differences, p = 0.94 [Figure 7], p = 0.91 [Figure 8] and p = 0.94 [Figure 9]).

Ventilation time: Eight studies reported this outcome (Figure 10). On average, no significant effect of any combination of EN with PN on the duration of mechanical ventilation (MD -0.43, CI -1.50 to 0.63, p = 0.42) with substantial statistical heterogeneity ($I^2 = 79\%$) were observed. There was no difference in the sensitivity analyses (MD -0.59, 95% CI, -1.97 to 0.79, p=0.40).

There was no difference in the treatment effect in RCTs using EN+PN vs. those using SPN, RCTs published until 2000 vs. those published after 2000, nor in RCTs patients with or without a baseline nutrition risk assessment (test for subgroup differences, p = 0.83 [Figure 10], p = 0.31 [Figure 11] and p = 0.79 [Figure 12]), nor in sensitivity analysis.

Critical Care Nutrition: Systematic Reviews May 2021

Blood sugars: Blood sugar levels were reported by four trials. Glycaemia was significantly higher in the EN+PN group compared to the EN in the RCT by Bauer et al. on day 7 only (p<0.05). On the contrary, Chiarelli et al. observed no difference in glycemia between the groups, but no numbers were reported. Heidegger et al. reported similar glucose control in both groups and Berger et al. reported similar area under the curves of glycemia.

Nutrition delivery: Trials reported nutritional data in a non-uniform manner (Table 2) which precluded statistical aggregation. A combination of EN with PN compared EN alone significantly increased energy intake in six trials, while in two trials differences between groups were not observed. Regarding protein, significant increases of delivery in the combination of EN with PN groups were observed in four trials, while one trial reported no difference.

Physical and Quality of Life Outcomes: Four studies reported on these outcomes displayed in Table 3. None of the trials found significant differences between groups. However, Wischmeyer et al. found trends towards improved handgrip strength at hospital discharge, improved 6 Minute Walk Test and better Barthel index at hospital discharge, as well as improved SF-36 scores at 6 months in the nutritionally high-risk patients that received a combination of EN and PN. Berger et al. observed a trend for a lower loss of the quadriceps cross sectional area in those patients receiving SPN.

Conclusions: In critically ill patients, the combined use of EN and PN, compared to EN alone,

- 1) may be associated greater amounts of macronutrients administered
- 2) has no effect on mortality, infectious complications, duration of mechanical ventilation, ICU and Hospital LOS.
- 3) may be associated with some improvements in long-term physical function of surviving critically ill patients.
- 4) may be associated with a trend towards reduced mortality in nutritionally at-risk patients but data are too sparse to make any conclusions really.

Table 1. Randomized studies evaluating combined EN + PN in critically ill patients

Study	Population	Intervention		
_			Co-Intervention	Study Period
Trials compar	ring EN+PN with EN			
Herndon 1987 ⁴⁴	28 patients with burns > 50 % TBSA	EN+PN vs. EN	Albumin and hourly feedings (milk or commercial EN) for all	Day 0-10 post-injury
Herndon 1989 ⁴⁵	39 patients with burns > 50 % TBSA	EN+PN vs. EN	Albumin and hourly feedings (milk or commercial EN) for all	NR, presumably day 0-14 post-injury
Dunham 1994 42	37 blunt trauma patients	EN+PN vs. EN vs. PN# PN made up 50% of given calories	NR	Randomized < 30 hours after injury
Chiarelli 1996 33	24 ICU patients medical and surgical	EN+PN vs. EN PN made up 50% of given calories, TPN for all patients on days 1-3	NR	Intervention starting day 4, duration NR
Bauer 2000 ⁴⁰	120 patients expected to eat less than 20 kcal/kg daily for 2 d	EN+PN vs. EN+placebo PN : 120 ml/h of 1 kcal/ml for 18-24 hours EN : bolus feeding up to 350 ml of 1kcal/mL standard formula	GRV > 300 ml : feeding delayed by 4 hours and cisapride was added	Started early, continued for 4-7 days
Abrishami 2010 ³⁹	20 SIRS patients with APACHE II > 10 and expected not to feed orally for ≥5 d	EN+PN vs. EN EN+PN : EN + 500 ml of 10% amino acid solution + 500 ml of dextrose 50% solution	Metocloparamide if GRV >300 ml	Days 1-7 after admission
Casaer 2011 35, 48	2312 ICU patients, NRS > 3, all patients who were unable to eat by day 2 received enteral nutrition and expected to remain on IU for more than 5 further days	EN+PN vs. EN EN+PN : 20% glucose solution (400 kcal day 1, 800 kcal day 2), day 3: PN+EN at 100%, when EN covered 80% or patient fed orally, PN was reduced / stopped. PN was restarted whenever enteral or oral intake fell to less than 50% of the calculated caloric needs.	Prokinetic agents	Days 1-7 but PN not started until day 3
Chen 2011 ³²	147 elderly patients in respiratory ICU	EN+PN vs. EN vs. PN# PN to make up kcal and nitrogen deficit; EN: 100ml/hr=goal rate	Metoclopramide if GRV>200mL, NJ if not tolerating NG	NR, comparison of groups on day 7
Wischmeyer 2017 ⁴⁷	125 adult (<u>></u> 18 years) mixed ICU patients with BMI <25 or >35, mNUTRIC score <5 / >5	EN+PN vs. EN PN adjusted daily to reach 100% of goal calories. In extubated patients, until 50% of calories goal were tolerated orally	No	Days 1-7 or until death
	ring SPN with EN			
Heidegger 2013 ⁴³	305 ICU-patients requiring treatment > 5 d, not achieving 60% of calculated energy target by end of day 3	SPN vs. EN EN progression encouraged in both groups.	Prokinetic agents (<u>></u> 300 ml)	4-8 days post randomization 28 day follow-up
Ridley 2018 46	100 adult (≥16 years) mixed ICU patients not achieving 80% of target within first 48-72 hours of admission.	SPN vs. EN SPN to provide 80% of goal energy based on amount of EN received.	No	7 days or until ICU discharge/ oral nutrition s
Berger 2019 41	23 mechanically ventilated patients who by end of day 3 did not receive >60% of equation target	SPN vs. EN EN alone for all patients days 1-3	No	6 days post randomization and 15 and 28 days follow- up

Study	Mortality	/ # (%) †	Infectio	ns # (%) ‡	LOS in	days	Ventilator	days	0	Other		
	Combination of EN and PN	EN	Combination of EN and PN	EN	Combination of EN and PN	EN	Combination of EN and PN	EN	Combination of EN and PN	EN		
Trials compar	ing EN+PN with EN		-		•				-			
Herndon 1987 ⁴⁴	8/13 (62)	8/15 (53)	NR	NR	NR	NR	NR	NR		IR		
Herndon 1989 45	> Day 14 10/16 (63)	> Day 14 6/23 (26)	NR	NR	NR	NR	NR	NR	1	IR		
Dunham 1994 ⁴²	3/10 (30)	1/12 (8.3)	NR	NR	NR	NR	NR	NR		n related ications 3/12 (25)		
Chiarelli 1996 ³³	3/12 (25)	4/12 (33)	Bloodstream 5/12 (42) Bronchial aspirate 7/12 (58) Positive chest X- ray 6/12 (50)	Bloodstream 5/12 (42) Bronchial aspirate 6/12 (50) Positive chest X-ray 3/12 (25)	Hospital 37 ± 13	Hospital 41 ± 23	19 ± 6	19 ± 2		JR		
Bauer 2000 40	< Day 4: 3/60 (5) 90-day: 17/60 (28)	< Day 4: 4/60 (6.7) 90-day: 18/60 (30)	39/60 (65)	39/60 (65)	ICU 16.9 ± 11.8 Hospital 31.2 ± 18.5	ICU 17.3 ± 12.8 Hospital 33.7 ± 27.7	11 ± 9	10 ± 8	Glycemia o 1.16 ± 0.36	n day 7 (g/L) 1.31 ± 0.49		
Abrishami 2010 ³⁹	2/10 (20)	1/10 (10)	NR	NR	ICU 25.7 Hospital 37.4	ICU 27.7 Hospital 36.5	NR	NR	1	IR		
Casaer 2011 35, 48	ICU 146/2312 (6.3) Hospital 251/2312 (10.9) Within 90 post enrollment 255/2312(11.2)	ICU 141/2328 (6.1) Hospital 242/2328 (10.4) Within 90 post enrollment 257/2328 (11.2)	Any 605/2312 (26.2) Airway or lung 447/2312 (19.3) Bloodstream 174/2312 (7.5) Wound 98/2312(4.2) Urinary tract 72/2312 (3.1)	Any 531/2328 (22.8) Airway or lung 381/2328 (16.4) Bloodstream 142/2328 (6.1) Wound 64/2328 (2.7) Urinary tract 60/2328 (2.6)	ICU 5.05 ±5.19 4 [2-9] Hospital 18.1 ±14.83 16 [9-29]	ICU 4.05 ±3.7 3 [2-7] Hospital 16.8 ± 13.35 14 [9-27]	2.7 ± 2.96 2 [1-5]	2.7 ± 2.96 2 [1-5]	Median dura renal-replac 10 [5-23]	y failure tion (days) of ement therapy 7 [3-16]		
Chen 2011 ³²	20-day 3/49 (6)	20-day 11/49 (22)	6/49 (12)	5/49 (10)	ICU 6.75 ± 1.8 Hospital 17.3 ± 2.5	ICU 9.1 ± 2.8 Hospital 23.32 ± 5.6	5.76 ± 1.56	8.0 ± 2.1	"Other cor 8/49 (16)	nplications" 10/49 (20)		

Table 1. Randomized studies evaluating combination parenteral nutrition and enteral nutrition in critically ill patients (continued)

Critical Care Nutrition: Systematic Reviews May 2021

Wischmeyer	ICU:	ICU:	38/52	46/73	ICU*	ICU*	*	*		NR
2017 ⁴⁷	7/52 (13.5) Hospital: 8/52 (15.4)	13/73 (17.8) Hospital: 17/73 (23.3)			16.7 ± 13.5 Hospital* 39.9 ± 61.9	14.2 ± 9.2 Hospital* 29.6 ± 22.6	11.1 <u>+</u> 11.3	10.4 <u>+</u> 8.7		
	ng SPN with EN	-								
Heidegger 2013 ⁴³	ICU: 8/153 (5) 28-day: 20/153 (13)	ICU: 11/152 (7) 28-day: 28/152 (18)	Day 4 – 28 * 77/153 (50)	Day 4 – 28 * 85/152 (56)	ICU 13 ± 10 Hospital 31 ± 23	ICU 13 ± 11 Hospital 32 ± 23	2.5 ± 4.6	2.8 ± 4.2	EN+PN an	se control in the d EN groups, < 8 mmol/l
Ridley 2018 ⁴⁶	ICU: 15/51 Hospital: 16/51 90-day: 19/51 180-day: 19/51	ICU: 11/48 Hospital: 11/48 90-day: 13/48 180-day: 13/48	NR	NR	ICU* 13 ± 10 Hospital 22 ± 21	ICU* 13.9 ± 11.7 Hospital 23 ± 17	* 12.2 ± 8.3	* 12.8 ± 10.1	Vor 3/51	niting 18/48
Berger 2019 41	0/11 /(0)	1/12 (8.3)	1 [1-1] n=11	1 [1-2] n=12	ICU 16.01 ± 8.09 15.3 [10.6- 17.4] Hospital 45.36 ± 20.51 44 [30-57]	ICU 15.74 ± 12.74 9.5 [7.1- 24.4] Hospital 46.91 ± 25.13 48 [25-59]	11 ± 7.66 8.9 [4.9-15.7]	9.5 ± 8.5 5.5 [4.2- 14.5]	betwee Net protein bre	mia did not differ en groups akdown similar to th groups
refers to the # c enteral nutrition	of patients with infect , GRV: Gastric resid	tions unless specific dual volume, ICU: ir	ed, , Abbreviations: AUC itensive care unit, NG: r	rom author in mean and 3 C: area under the curve, a nasogastric tube, NJ: nas se syndrome, TBSA: Tota	APACHE II: Acute ojejunal tube, NR	e Physiology An R: not reported, I	d Chronic Health	Evaluation	II, BMI: body mas	ss index; EN:

Table 2. Delivery of Nutrients

Study	Calorie target		Calories delivered		Protein target	Protein delivered				
		Combination EN and PN	EN	Comparison between groups: p-Value		Combination EN and PN	EN	Comparison between groups: p-Value		
Trials compari	ing EN+PN with EN									
Herndon 1987 ⁴⁴	25 kcal/kg/d+ 40 kcal/%TBSA	Day 0-3: 3421 ± 336 kcal/d Days 4-7: 3997 ±304 kcal/d Days 8-10: 4191 ±485 kcal/d	Day 0-3: 321± 177 kcal/d Days 4-7: 1494 ±358 kcal/d Days 8-10: 1876 ±541 kcal/d	<0.05 for days 0-7; NS for days 8-10	NR	NR	NR	-		
Herndon 1989 ⁴⁵	25 kcal/kg/d + 40 kcal/%TBSA	Survivors: 3080 ±177 kcal/d Nonsurvivors: 2952 ± 415 kcal/d	Survivors: 1994 ± 217 kcal/d Nonsurvivors: 498 ±422 kcal/d	*<0.05; between survivors and nonsurvivors	NR	NR	NR	-		
Dunham 1994 ⁴²	1.3 x basal energy expenditure by HBE	Days 1-7: 2067 ± 499 (n=3)	Days 1-7: 2097 ± 552 (n=6)	NS	1.75 g/kg/day	Days 1-7: 222 ±31 (n=3)	Days 1-7: 129 ± 35 (n=6)	NS		
Chiarelli 1996 33	No reported	$31 \pm 6 \text{ kcal/kg/d}$	$33 \pm 9 \text{ kcal/kg/d}$	NS difference of lost calories	NR	NR	NR	-		
Bauer 2000 40	25 kcal/kg/d	Day 4: 11 ±3.3 kcal/kg Day 7†: 14.8±4.6 kcal/kg	Day 4: 9.9 ±3.9 Day 7: 13.2 ±4.3	Day 4: 0.25 Day 7: 0.6	1 gram of N per 100 kcal of carbohydrates-fat	NR	NR	-		
Abrishami 2010 ³⁹	NR	NR	NR	-	NR	NR	NR	-		
Casaer 2011 35, 48	Day 1: 400 kcal/ Day 2: 800 kcal/d Day 3: 100% kcal/d Max goal: 2880 kcal/d	NR	NR	-	NR	NR	NR	-		
Chen 2011 32	NR	NR	NR	-	NR	NR	NR	-		
Wischmeyer 2017 ⁴⁷	BMI <25: 25 kcal/actual BW/d; BMI >35 20 kcal/adjusted BW/d	Days 0-7: 95 ± 13%; Day 0-27: 90 ± 16%	Days 0-7: 69 ± 28%; Day Days 0-27: 72 ± 25%	Days 0-7: <0.001 Days 0-27: <0.001	BMI <25: 1.2 g/kg actual BW/d; BMI >35: 1.2/g kg adjusted BW/d	Days 0-7 : 86 ± 16% Day 0-27: 82 ± 19%	Days 0-7: 64 ± 26% Day 0-27: 68 ± 25 %	Days 0-7: <0.001 Days 0-27: <0.001		

Table 3. Physical Outcomes

Study	Combination of EN + PN	EN alone	P Value										
Chen 2011	Changes in respiratory muscle strength before and after nutrition sup	port (cmH ₂ O) *											
	Before: 28.34 ± 9.49 Day 7: 34.32 ± 15.43 P=0.025	Before: 26.75 ± 11.6 Day 7: 32.3 ± 10.3 P=0.011											
/ischmeyer 2017	Handgrip strength in kg #												
	ICU discharge: 9 (43) [unable-25]	ICU discharge: Unable (62) [unable-18]	P=0.21										
	Hospital discharge: 12 (36) [unable-33]	Hospital discharge: Unable (56) [unable-20]	P=0.14										
	6-minute walk test at hospital discharge #												
	Unable (40) [unable-0]	Unable (60) [unable-unable]	P=0.2										
	Barthel Index at hospital discharge *												
	61.1 ± 32.4 (28)	46.5 ± 32.1 (41)	P=0.08										
	SF-36: standardized physical component scale *												
	3 months: 33.3 ± 10.1 (22) 6 months: 39.3 ± 10.2 (20)	3 months: 35.3 ± 10.8 (27) 6 months: 35.8 ± 11.2 (30)	P= 0.38 P=0.17										
	SF-36: standardized mental component scale *												
	3 months: 51.5 ± 10.0 (22) 6 months: 49.0 ± 13.5 (20)	3 months: 50.0 ± 10.5 (27) 6 months: 43.2 ± 14.8 (30)	P=0.38 P=0.11										
Ridley	Hand grip at hospital discharge in kg *												
2018	19 ± 13.5 (19)	20 ± 8, (24)	P=0.71										
	ICU mobility scale at hospital discharge #												
	9 [5-10], (25)	8 [4-10] (33)	P=0.58										
		EQ-5D-3L *											
	Hospital discharge: 0.25 ± 0.34 (27) 90 days: 0.69 ± 0.24 (35) 180 days: 0.75 ± 0.26 (35)	Hospital discharge: 0.32 ± 0.36 (17) 90 days: 0.76 ± 0.23 (29) 180 days: 0.77 ± 0.2 (29)	P=0.54 P=0.29 P=0.76										
Berger 2019	Difference of quadriceps cross sectional area between days 4 and 15	Difference of quadriceps cross sectional area between days 4 and 15 after admission											
	-16%	-21%											

Figure 1. Mortality, Subgroup Analysis: Type of nutrition

	EN+F	N N	SPN	1		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
2.1.1 EN+PN vs. EN								
Herndon 1987	8	13	8	15	10.1%	1.15 [0.61, 2.19]	1987	_
Herndon 1989	10	16	6	23	7.5%	2.40 [1.09, 5.26]	1989	
Dunham 1994	3	10	1	12	1.3%	3.60 [0.44, 29.45]	1994	
Chiarelli 1996	3	12	4	12	3.3%	0.75 [0.21, 2.66]	1996	
Bauer 2000	17	60	18	60	12.2%	0.94 [0.54, 1.65]	2000	_ _
Abrishami 2010	2	10	1	10	1.1%	2.00 [0.21, 18.69]	2010	
Chen 2011	3	49	11	49	3.6%	0.27 [0.08, 0.92]	2011	
Casaer 2011	251	2312	242	2328	29.7%	1.04 [0.88, 1.23]	2011	+
Wischmeyer 2017	8	52	17	73	7.8%	0.66 [0.31, 1.41]	2017	
Subtotal (95% CI)		2534		2582	76.6%	1.03 [0.76, 1.39]		•
Total events	305		308					
Heterogeneity: $Tau^2 = 0$ Test for overall effect: 2				(P = 0.1	3); ² = 36%	/o		
2.1.2 SPN vs. EN								
Heidegger 2013	20	153	28	152	13.1%	0.71 [0.42, 1.20]		
Ridley 2018	16	51	11	48	9.7%	1.37 [0.71, 2.65]		· · · · ·
Berger 2019 Subtotal (95% Cl)	0	11 215	1	12 212	0.6% 23.4%	0.36 [0.02, 8.04] 0.92 [0.54, 1.56]	2019	
Total events	36		40					
Heterogeneity: Tau ² = 0	0.06; Chi ²	= 2.68	, df = 2 (F	P = 0.26	6); l² = 25%			
Test for overall effect: 2	Z = 0.32 (P = 0.7	5)		-			
Total (95% CI)		2749		2794	100.0%	1.00 [0.79, 1.28]		+
Total events	341		348					
Heterogeneity: Tau ² = 0 Test for overall effect: 2				(P = 0	.16); l² = 30	0%		0.05 0.2 1 5 20 Combination EN and PN EN
Test for subgroup differ	rences: C	hi² = 0.	13, df = 1	(P = 0	.72), l² = 0%	6		

Figure 2. Mortality, Subgroup Analysis: Publication Year

(Combination of EN	and PN	EN			Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
3.1.1 Trials published b	efore 2000							
Herndon 1987	8	13	8	15	10.1%	1.15 [0.61, 2.19]	1987	
Herndon 1989	10	16	6	23	7.5%	2.40 [1.09, 5.26]	1989	
Dunham 1994	3	10	1	12	1.3%	3.60 [0.44, 29.45]	1994	
Chiarelli 1996	3	12	4	12	3.3%	0.75 [0.21, 2.66]	1996	
Bauer 2000	17	60	18	60	12.2%	0.94 [0.54, 1.65]	2000	
Subtotal (95% CI)		111		122	34.4%	1.27 [0.82, 1.94]		◆
Total events	41		37					
Heterogeneity: $Tau^2 = 0$.	.06; Chi ² = 5.26, df	= 4 (P = 0.2	6); I ² = 2	4%				
Test for overall effect: Z	= 1.08 (P = 0.28)							
3.1.2 Trials published a	fter 2005							
Abrishami 2010	2	10	1	10	1.1%	2.00 [0.21, 18.69]	2010	
Casaer 2011	251	2312	242	2328	29.7%	1.04 [0.88, 1.23]	2011	+
Chen 2011	3	49	11	49	3.6%	0.27 [0.08, 0.92]	2011	
Heidegger 2013	20	153	28	152	13.1%	0.71 [0.42, 1.20]	2012	- +
Wischmeyer 2017	8	52	17	73	7.8%	0.66 [0.31, 1.41]	2017	
Ridley 2018	16	51	11	48	9.7%	1.37 [0.71, 2.65]	2018	
Berger 2019	0	11	1	12	0.6%	0.36 [0.02, 8.04]	2019	
Subtotal (95% CI)		2638		2672	65.6%	0.88 [0.64, 1.20]		•
Total events	300		311					
Heterogeneity: Tau ² = 0.	.05; Chi² = 9.07, df	= 6 (P = 0.1	7); l² = 3	4%				
Test for overall effect: Z	= 0.80 (P = 0.42)							
Total (95% CI)		2749		2794	100.0 %	1.00 [0.79, 1.28]		◆
Total events	341		348					
Heterogeneity: Tau ² = 0.	.04; Chi² = 15.63, d	lf = 11 (P = 0	0.16); I ≊÷	= 30%			-	0.02 0.1 1 10 50
Test for overall effect: Z							Favor	U.U.2 U.1 1 10 50 urs Combination of EN and PN Favours EN
Test for subgroup differ	ences: Chi ² = 1.81	df = 1 (P =	0.18), I ^z	= 44.7	%		Favol	ans compination of EN and FIN Favours EN

Figure 3. Mortality, Subgroup Analysis: Nutrition Risk Assessment

С	ombination of EN a	nd PN	EN			Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
4.1.1 Trials with nutrition	nal assessment							
Bauer 2000	17	60	18	60	12.2%	0.94 [0.54, 1.65]	2000	
Abrishami 2010	2	10	1	10	1.1%	2.00 [0.21, 18.69]	2010	
Chen 2011	3	49	11	49	3.6%	0.27 [0.08, 0.92]	2011	
Casaer 2011	251	2312	242	2328	29.7%	1.04 [0.88, 1.23]	2011	+
Wischmeyer 2017 Subtotal (95% CI)	8	52 2483	17	73 2520	7.8% 54.4 %	0.66 [0.31, 1.41] 0.87 [0.62, 1.24]	2017	•
Total events	281		289					
Heterogeneity: Tau ² = 0.0	05; Chi² = 6.22, df =	4 (P = 0.	18); I 2 = 3	6%				
Test for overall effect: Z =	: 0.75 (P = 0.45)							
4.1.2 Trials without nutr	itional assessmen	t						
Herndon 1987	8	13	8	15	10.1%	1.15 [0.61, 2.19]	1987	_
Herndon 1989	10	16	6	23	7.5%	2.40 [1.09, 5.26]	1989	
Dunham 1994	3	10	1	12	1.3%	3.60 [0.44, 29.45]	1994	
Chiarelli 1996	3	12	4	12	3.3%	0.75 [0.21, 2.66]	1996	
Heidegger 2013	20	153	28	152	13.1%	0.71 [0.42, 1.20]	2012	
Ridley 2018	16	51	11	48	9.7%	1.37 [0.71, 2.65]	2018	+-
Berger 2019 Subtotal (95% CI)	0	11 266	1	12 274	0.6% 45.6 %	0.36 [0.02, 8.04] 1.17 [0.78, 1.77]	2019	
Total events	60		59					
Heterogeneity: Tau ² = 0.0	09; Chi ^z = 8.99, df =	6 (P = 0.	17); I ^z = 3	3%				
Test for overall effect: Z =	0.77 (P = 0.44)	-						
Total (95% CI)		2749		2794	100.0%	1.00 [0.79, 1.28]		•
Total events	341		348					
Heterogeneity: Tau ² = 0.0	04; Chi² = 15.63, df	= 11 (P =	0.16); l²:	= 30%				0.01 0.1 1 10 100
Test for overall effect: Z =							C	ombination of EN and PN EN
Test for subgroup differe	nces: Chi ² = 1.15, d	if = 1 (P =	= 0.28), I ²	= 12.9	%		0	

Figure 4. Hospital LOS, Subgroup Analysis: Type of nutrition

	E	EN+PN	-	-	SPN			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% CI
2.4.1 EN+PN vs. EN										
Chiarelli 1996	37	13	12	41	23	12	5.7%	-4.00 [-18.95, 10.95]	1996	
Bauer 2000	31.2	18.5	60	33.7	27.7	60	11.7%	-2.50 [-10.93, 5.93]	2000	
Chen 2011	17.3	2.47	49	23.32	5.6	49	21.8%	-6.02 [-7.73, -4.31]	2011	
Casaer 2011	18.1	14.83	2312	16.8	13.35	2328	22.5%	1.30 [0.49, 2.11]	2011	+
Wischmeyer 2017 Subtotal (95% CI)	39.9	61.9	52 2485	29.6	22.6	73 2522	4.5% 66.2%	10.30 [-7.30, 27.90] -1.56 [-7.08, 3.96]	2017	
Heterogeneity: Tau ² =	24.22; 0	Chi² = 59	9.16, df	= 4 (P	< 0.000	01); l² =	= 93%			
Test for overall effect:	Z = 0.55	5 (P = 0.	.58)							
2.4.2 SPN vs. EN										
Heidegger 2013	31	23	153	32	23	152	16.8%	-1.00 [-6.16, 4.16]	2012	
Ridley 2018	22	21	51	23	17	48	13.0%	-1.00 [-8.51, 6.51]	2018	
Berger 2019	45.36	20.51	11	46.91	25.13	12	4.1%	-1.55 [-20.23, 17.13]	2019	
Subtotal (95% CI)			215			212	33.8%	-1.03 [-5.17, 3.12]		
Heterogeneity: Tau ² =	0.00; Cł	ni² = 0.0	0, df =	2 (P = 1	.00); I²	= 0%				
Test for overall effect:	Z = 0.49) (P = 0.	.63)							
Total (95% CI)			2700			2734	100.0%	-1.44 [-5.59, 2.71]		-
Heterogeneity: Tau ² =	19.79; 0	Chi² = 59	9.36, df	= 7 (P	< 0.000	01); l² =	= 88%			-20 -10 0 10 20
Test for overall effect:										-20 -10 0 10 20 Combination EN and PN EN
Test for subgroup diffe	erences:	Chi ² = (0.02, df	= 1 (P =	= 0.88),	l² = 0%	, D			

Figure 5. Hospital LOS, Subgroup Analysis: Publication Year

	Ē	N+PN			SPN			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
3.5.3 Trials publishe	d until 20	000								
Chiarelli 1996	37	13	12	41	23	12	3.7%	-4.00 [-18.95, 10.95]	1996	;
Bauer 2000	31.2	18.5	60	33.7	27.7	60	10.1%		2000)
Subtotal (95% CI)			72			72	13.8%	-2.86 [-10.20, 4.48]		
Heterogeneity: Tau² =	= 0.00; C	hi² = 0.0)3, df=	1 (P = 0)	.86); l² :	= 0%				
Test for overall effect	: Z = 0.76	6 (P = 0.	44)							
3.5.4 Trials publishe	d after 2	005								
Chen 2011	17.3	2.47	49	23.32	5.6	49	48.0%	-6.02 [-7.73, -4.31]	2011	
Casaer 2011	0	0	0	0	0	0		Not estimable	2011	
Heidegger 2013	31	23	153	32	23	152	20.9%	-1.00 [-6.16, 4.16]	2012	2
Wischmeyer 2017	39.9	61.9	52	29.6	22.6	73	2.7%	10.30 [-7.30, 27.90]	2017	·
Ridley 2018	22	21	51	23	17	48	12.2%	-1.00 [-8.51, 6.51]	2018	3
Berger 2019	45.36	20.51	11	46.91	25.13	12		-1.55 [-20.23, 17.13]	2019	
Subtotal (95% CI)			316			334	86.2%	-2.73 [-6.82, 1.36]		
Heterogeneity: Tau ² =			-	4 (P = 0)	l.10); l²÷	= 48%				
Test for overall effect	: Z = 1.31	(P = 0.	19)							
Total (95% CI)			388			406	100.0%	-3.38 [-6.34, -0.42]		•
Heterogeneity: Tau ² =	= 3.98; C	hi ² = 8.1	4, df =	6 (P = 0	.23); I ²÷	= 26%				-20 -10 0 10 20
Test for overall effect	: Z = 2.24	+ (P = 0.	03)							Combination EN and PN EN
Test for subgroup dif	ferences	: Chi = =	0.00, c	lf = 1 (P	= 0.97)	. I ^z = 0%	6			

Figure 6. Hospital LOS, Subgroup Analysis: Nutrition Risk Assessment

	E	N+PN			SPN			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
4.5.3 Trials with nutr	ritional a	ssessn	nent							
Bauer 2000	31.2	18.5	60	33.7	27.7	60	11.7%	-2.50 [-10.93, 5.93]	2000	
Casaer 2011	18.1	14.83	2312	16.8	13.35	2328	22.5%	1.30 [0.49, 2.11]	2011	-
Chen 2011	17.3	2.47	49	23.32	5.6	49	21.8%	-6.02 [-7.73, -4.31]	2011	-
Vischmeyer 2017 Subtotal (95% Cl)	39.9	61.9	52 2473	29.6	22.6	73 2510	4.5% 60.4 %		2017	•
- Heterogeneity: Tau ² =	= 24.86; (Chi ² = 5	8.89, di	f= 3 (P -	< 0.000	01); I ^z =	95%			
est for overall effect	: Z = 0.43) (P = 0.	67)	-						
.5.4 Trials without r	nutritiona	al asse:	ssment	t						
Chiarelli 1996	37	13	12	41	23	12	5.7%	-4.00 [-18.95, 10.95]	1996	
leidegger 2013	31	23	153	32	23	152	16.8%	-1.00 [-6.16, 4.16]	2012	
Ridley 2018	22	21	51	23	17	48	13.0%	-1.00 [-8.51, 6.51]	2018	
Berger 2019 Subtotal (95% CI)	45.36	20.51	11 227	46.91	25.13	12 224	4.1% 39.6 %	-1.55 [-20.23, 17.13] - 1.24 [-5.24, 2.76]	2019	•
Heterogeneity: Tau ² =	= 0.00; Cl	hi ² = 0.1	4. df=	3 (P = 0	.99); i ² :	= 0%				_
est for overall effect			•							
otal (95% CI)			2700			2734	100.0%	-1.44 [-5.59, 2.71]		•
Heterogeneity: Tau ² =	= 19.79; (Chi ² = 5	9.36, di	f= 7 (P	< 0.000	01); I 2 =	88%			-20 -10 0 10 20
est for overall effect										-20 -10 0 10 20 Combination EN and PN EN
Fest for subgroup dif	ferences	: Chi ^z =	0.00, d	lf=1 (P	= 0.99)	.l ^z = 09	6			

Figure 7. ICU LOS, Subgroup Analysis: Type of nutrition

	E	N+PN			SPN			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% CI
2.3.1 EN+PN vs. EN										
Bauer 2000	16.9	11.8	60	17.3	12.8	60	10.5%	-0.40 [-4.81, 4.01]	2000	
Chen 2011	6.75	1.75	49	9.09	2.75	49	22.6%	-2.34 [-3.25, -1.43]	2011	
Casaer 2011	5.05	5.19	2312	4.05	3.7	2328	23.8%	1.00 [0.74, 1.26]	2011	
Wischmeyer 2017 Subtotal (95% CI)	16.7	13.5	52 2473	14.2	9.2	73 2510	10.9% 67.8%	2.50 [-1.73, 6.73] -0.05 [-2.58, 2.47]	2017	
Heterogeneity: Tau ² =				= 3 (P <	< 0.000	01); l² =	= 94%			
Test for overall effect:	Z = 0.04	(P = ().97)							
2.3.2 SPN vs. EN										
Heidegger 2013	13	10	153	13	11	152	17.5%	0.00 [-2.36, 2.36]	2012	
Ridley 2018	13	10	51	13.9	11.7	48	10.7%	-0.90 [-5.20, 3.40]	2018	
Berger 2019 Subtotal (95% Cl)	16.01	8.09	11 215	15.74	12.74	12 212	4.0% 32.2%	0.27 [-8.38, 8.92] -0.18 [-2.19, 1.83]	2019	
Heterogeneity: Tau ² =	0.00; Cł	ni² = 0.	14, df =	= 2 (P =	0.93); l ^a	² = 0%				
Test for overall effect:	Z = 0.18	8 (P = (0.86)							
Total (95% CI)			2688			2722	100.0%	-0.15 [-2.05, 1.75]		-
Heterogeneity: Tau ² =				= 6 (P <	< 0.000	01); I² =	88%			-10 -5 0 5 10
Test for overall effect: Test for subgroup diffe			-	lf = 1 (P	= 0.94). $ ^2 = 0^2$	%			Combination EN and PN EN

Figure 8. ICU LOS, Subgroup Analysis: Publication Year

-	E	N+PN	-		SPN			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
3.4.3 Trials publishe	d until 20	000								
Bauer 2000 Subtotal (95% CI)	16.9	11.8	60 60	17.3	12.8	60 60	10.5% 10.5 %	-0.40 [-4.81, 4.01] - 0.40 [-4.81, 4.01]	2000	
Heterogeneity: Not ap	pplicable	9								
Test for overall effect	:Z=0.18	8 (P = 0	0.86)							
3.4.4 Trials publishe	d after 2	005								
Casaer 2011	4	5.19	2312	3	3.7	2328	23.8%	1.00 [0.74, 1.26]	2011	•
Chen 2011	6.75	1.75	49	9.09	2.75	49	22.6%	-2.34 [-3.25, -1.43]	2011	
Heidegger 2013	13	10	153	13	11	152	17.5%	0.00 [-2.36, 2.36]	2012	
Wischmeyer 2017	16.7	13.5	52	14.2	9.2	73	10.9%	2.50 [-1.73, 6.73]	2017	
Ridley 2018	13	10	51	13.9	11.7	48	10.7%	-0.90 [-5.20, 3.40]	2018	
Berger 2019 Subtotal (95% CI)	16.01	8.09	11 2628	15.74	12.74	12 2662	4.0% 89.5 %	0.27 [-8.38, 8.92] - 0.11 [-2.16, 1.94]	2019	
Heterogeneity: Tau ² =	= 4.14; C	hi² = 4	9.22, d	f=5(P <	0.000	01); I ^z =	90%			
Test for overall effect	:Z=0.11	(P=(0.92)							
Total (95% CI)			2688			2722	100.0%	-0.15 [-2.05, 1.75]		-
Heterogeneity: Tau ² =	= 3.94; C	hi²=4	9.47, d	f=6(P <	< 0.000	01); I ² =	88%			
Test for overall effect	: Z = 0.16	5 (P = 0	0.88)							Combination EN and PN EN
Test for subgroup dif	ferences	:: Chi ≃	= 0.01,	df = 1 (F	^o = 0.91), I ^z = 0	%			

Figure 9. ICU LOS, Subgroup Analysis: Nutrition Risk Assessment

	-	N+PN			SPN			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
4.4.3 Trials with nutr	itional a	ssess	ment							
Bauer 2000	16.9	11.8	60	17.3	12.8	60	10.5%	-0.40 [-4.81, 4.01]	2000	
Chen 2011	6.75	1.75	49	9.09	2.75	49	22.6%	-2.34 [-3.25, -1.43]	2011	
Casaer 2011	5.05	5.19	2312	4.05	3.7	2328	23.8%	1.00 [0.74, 1.26]	2011	
Wischmeyer 2017 Subtotal (95% CI)	16.7	13.5	52 2473	14.2	9.2	73 2510	10.9% 67.8 %	2.50 [-1.73, 6.73] - 0.05 [-2.58, 2.47]	2017	-
Heterogeneity: Tau ² =	= 4.90; C	hi = 4	8.52, d	f=3(P <	< 0.000	01); I ^z =	94%			
Test for overall effect:	Z= 0.04	(P = 0).97)							
4.4.4 Trials without n										
Heidegger 2013	13	10	153	13	11	152	17.5%	0.00 [-2.36, 2.36]	2012	
Ridley 2018	13	10	51	13.9	11.7	48	10.7%	-0.90 [-5.20, 3.40]		
Berger 2019 Subtotal (95% Cl)	16.01	8.09	11 215	15.74	12.74	12 212	4.0% 32.2 %	0.27 [-8.38, 8.92] - 0.18 [-2.19, 1.83]	2019	
Heterogeneity: Tau ² =	= 0.00; C	hi² = O	.14, df:	= 2 (P =	0.93); l ^a	'= 0%				
Test for overall effect:	Z = 0.18) (P = (0.86)	-						
Total (95% CI)			2688			2722	100.0 %	-0.15 [-2.05, 1.75]		-
Heterogeneity: Tau ² =	-		-	f=6(P <	< 0.000	01); I² =	88%			-10 -5 0 5 10
Test for overall effect: Test for subgroup dif		•		df = 1_(F	^o = 0.94), I² = 0	%			Combination EN and PN EN

Figure 10. Ventilator days, Subgroup Analysis: Type of nutrition

		EN+PN	•		SPN			Mean Difference		Mean Difference		
Céudur an Cuib anaim						Tatal	Mainht		Vee			
Study or Subgroup	Mean	SD	Total	Mean	20	Total	Weight	IV, Random, 95% Cl	rear	· IV, Random, 95% Cl		
2.2.1 EN+PN vs. EN												
Chiarelli 1996	19	6	12	19	2	12	6.6%	0.00 [-3.58, 3.58]	1996	;		
Bauer 2000	11	9	60	10	8	60	8.3%	1.00 [-2.05, 4.05]	2000)		
Casaer 2011	2.7	2.96	2312	2.7	2.96	2328	25.8%	0.00 [-0.17, 0.17]	2011	•		
Chen 2011	5.76	1.56	49	7.95	2.11	49	23.1%	-2.19 [-2.92, -1.46]	2011			
Nischmeyer 2017	11.1	11.3	52	10.4	8.7	73	6.4%	0.70 [-2.96, 4.36]	2017			
Subtotal (95% CI)			2485			2522	70.1%	-0.44 [-1.98, 1.10]		\bullet		
Heterogeneity: Tau ² =	1.89; Cł	ni² = 33.	09, df =	= 4 (P <	0.000	01); l² =	= 88%					
Test for overall effect:	Z = 0.56	(P = 0.	57)									
		`	,									
2.2.2 SPN vs. EN												
leidegger 2013	2.5	4.625	153	2.75	4.21	152	21.2%	-0.25 [-1.24, 0.74]	2012	2 — -		
Ridley 2018	12.2	8.31	51	12.8	10.1	48	6.4%	-0.60 [-4.26, 3.06]	2018	;		
Berger 2019	11	7.66	11	9.5	8.5	12	2.4%	1.50 [-5.10, 8.10]	2019)		
Subtotal (95% CI)			215			212	29.9%	-0.24 [-1.19, 0.71]		•		
-leterogeneity: Tau ² =	0.00; Cł	ni² = 0.3	0, df =	2 (P = 0).86); I	² = 0%						
Test for overall effect:				,	,,							
		v	/									
Total (95% CI)			2700			2734	100.0%	-0.43 [-1.50, 0.63]		•		
-leterogeneity: Tau ² =	1.14; Cł	ni² = 33.	46, df =	= 7 (P <	0.000	1); l² =	79%					
Test for overall effect:				•		•				-4 -2 0 2 4		
Test for subgroup diffe		•	,	= 1 (P =	= 0.83). $ ^2 = 0$	%			Combination EN and PN EN		
and a second sec												

Figure 11. Ventilator Days, Subgroup Analysis: Publication Year

-	EN+PN				SPN		Mean Difference			Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl		
3.3.3 Trials published	d until 20	000										
Chiarelli 1996	19	6	12	19	2	12	9.1%	0.00 [-3.58, 3.58]	1996			
Bauer 2000	11	9	60	10	8	60	11.4%	1.00 [-2.05, 4.05]	2000			
Subtotal (95% Cl)			72			72	20.5%	0.58 [-1.74, 2.90]				
Heterogeneity: Tau ² =	: 0.00; Cl	hi ² = 0.1	7, df=	1 (P = 0	.68); l ^a	'= 0%						
Test for overall effect:	Z = 0.49	(P = 0.	62)									
3.3.4 Trials published	d after 2	005										
Casaer 2011	2	2.96	2312	2	2.96	2328		Not estimable	2011			
Chen 2011	5.76	1.56	49	7.95	2.11	49	30.5%	-2.19 [-2.92, -1.46]	2011			
Heidegger 2013	2.5	4.625	153	2.75	4.21	152	28.1%	-0.25 [-1.24, 0.74]	2012			
Nischmeyer 2017	11.1	11.3	52	10.4	8.7	73	8.8%	0.70 [-2.96, 4.36]	2017	•		
Ridley 2018	12.2	8.31	51	12.8	10.1	48	8.8%	-0.60 [-4.26, 3.06]	2018			
Berger 2019	11	7.66	11	9.5	8.5	12	3.3%		2019			
Subtotal (95% CI)			316			334	79.5%	-0.84 [-2.29, 0.60]		-		
Heterogeneity: Tau² =	•		•	= 4 (P =	0.02);	I ² = 66°	%					
Test for overall effect:	Z=1.14	(P = 0.	25)									
Fotal (95% CI)			388			406	100.0%	-0.57 [-1.83, 0.70]		-		
Heterogeneity: Tau ² =	: 1.22; Cl	hi ≃ = 14	.61, df:	= 6 (P =	0.02);	l ² = 59°	%					
Test for overall effect:	Z = 0.88	(P = 0.	38)							Combination EN and PN EN		
Test for subgroup diff	rences	: Chi ' =	1.04, d	lf=1 (P	= 0.31), I ² = 3	.8%					

	E	N+PN			SPN			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
4.3.3 Trials with nutr	itional as	ssessn	nent							
Bauer 2000	11	9	60	10	8	60	8.3%	1.00 [-2.05, 4.05]	2000	
Chen 2011	5.76	1.56	49	7.95	2.11	49	23.1%	-2.19 [-2.92, -1.46]	2011	
Casaer 2011	2.7	2.96	2312	2.7	2.96	2328	25.8%	0.00 [-0.17, 0.17]	2011	•
Wischmeyer 2017 Subtotal (95% Cl)	11.1	11.3	52 2473	10.4	8.7	73 2510	6.4% 63.5 %		2017	
Heterogeneity: Tau ² =	: 2.03; Cł	ni = 33	.09, df=	= 3 (P <	0.000	01); I ^z =	91%			
Test for overall effect:	Z = 0.56	(P = 0.	57)	*						
4.3.4 Trials without r	utritiona	lasses	sment							
Chiarelli 1996	19	6	12	19	2	12	6.6%	0.00 [-3.58, 3.58]	1996	· · · · · · · · · · · · · · · · · · ·
Heidegger 2013	2.5	4.625	153	2.75	4.21	152	21.2%	-0.25 [-1.24, 0.74]	2012	
Ridley 2018	12.2	8.31	51	12.8	10.1	48	6.4%	-0.60 [-4.26, 3.06]	2018	
Berger 2019	11	7.66	11	9.5	8.5	12	2.4%	1.50 [-5.10, 8.10]	2019	
Subtotal (95% Cl)			227			224	36.5%	-0.22 [-1.14, 0.69]		•
Heterogeneity: Tau ² =	: 0.00; Cł	ni² = 0.3	2, df=	3 (P = 0	.96); l ^a	²= 0%				
Test for overall effect:	Z = 0.47	(P = 0.	64)							
Total (95% CI)			2700			2734	100.0%	-0.43 [-1.50, 0.63]		•
Heterogeneity: Tau ² =	: 1.14; Cł	ni ² = 33	.46, df=	= 7 (P <	0.000	1); l² = i	79%			
Test for overall effect:				•						-4 -2 0 2 4 Combination EN and PN EN
Test for subgroup dif		•	•	f = 1 /P	- 0.70	0 12 - 0	06			Complication EN and EN EN

Figure 12 Ventilator Dave Subgroup Analysis: Nutrition Pick Assessment

References

- 1. Herndon DN, Barrow RE, Stein M, et al. Increased mortality with intravenous supplemental feeding in severely burned patients. The Journal of burn care & rehabilitation. 1989;10:309-313.
- 2. Herndon DN, Stein MD, Rutan TC, Abston S, Linares H. Failure of TPN supplementation to improve liver function, immunity, and mortality in thermally injured patients. The Journal of trauma. February 1987;27:195-204.
- 3. Dunham CM, Frankenfield D, Belzberg H, Wiles C, Cushing B, Grant Z. Gut failure--predictor of or contributor to mortality in mechanically ventilated blunt trauma patients? The Journal of trauma. July 1994;37:30-34.
- 4. Chiarelli AG, Ferrarello S, Piccioli A, et al. [Total enteral nutrition versus mixed enteral and parenteral nutrition in patients at an intensive care unit]. Minerva anestesiologica. 1996;62:1-7.
- 5. Bauer P, Charpentier C, Bouchet C, Nace L, Raffy F, Gaconnet N. Parenteral with enteral nutrition in the critically ill. Intensive care medicine. July 2000;26:893-900.
- 6. Abrishami R, Ahmadi A, Abdollahi M, et al. Comparison the inflammatory effects of early supplemental parenteral nutrition plus enteral nutrition versus enteral nutrition alone in critically ill patients. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2010;18:103-106.
- 7. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365(6):506-517. doi:10.1056/NEJMoa1102662
- 8. Chen F. Influence of different routes of nutrition on the respiratory muscle strength and outcome of elderly patients in respiratory intensive care unit. Chinese journal of clinical nutrition. 2011.
- 9. Wischmeyer PE, Hasselmann M, Kummerlen C, et al. A randomized trial of supplemental parenteral nutrition in underweight and overweight critically ill patients: the TOP-UP pilot trial. Critical care (London, England). June 2017;21:142.
- 10. Heidegger CP, Berger MM, Graf S, et al. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet (London, England). February 2013;381:385-393.
- 11. Ridley EJ, Davies AR, Parke R, et al. Supplemental parenteral nutrition versus usual care in critically ill adults: a pilot randomized controlled study. Critical care (London, England). January 2018;22:12.
- 12. Berger MM, Pantet O, Jacquelin-Ravel N, et al. Supplemental parenteral nutrition improves immunity with unchanged carbohydrate and protein metabolism in critically ill patients: The SPN2 randomized tracer study. Clin Nutr. Oct 2019;38(5):2408-2416.

Table 4. Excluded Articles

Author	Year	Reason for Exclusion
Altintas	2011	Intervention: no combination of EN and PN
		Methodological: no true randomization
Antebi	2004	Intervention: no combination of EN and PN, TPN for 5 days
Arabi	2011	Intervention/Control: no PN in either group, instead additional calories via propofol and dextrose in both groups
Arabi	2015	Intervention: only very small amount of calories received through PN (3-5 kcal/d)
Atkinson	1998	Intervention: no PN used in either group
Barbosa	2010	Intervention: EN started in both groups as soon as possible, but in no patient before day 6
Bastarache	2012	Intervention: no PN used in either group
Bost	2014	Type: Review
Boughton	2019	Patients: non-critically ill
Braunschweig	2015	Intervention: PN used in both groups (8/40 intervention group and 5/38 in control group)
Chapple	2019	Type: Review
Charles	2014	Intervention/Control: patients in both groups started on PN after 5-7 days if EN was not tolerated
Chelkeba	2017	Type: Systematic Review/ Meta-Analysis
Chuntrasakul	1996	Article missing, author contacted June 2019, May 2020 and June 2020 without response
Danielis	2019	Intervention: each patient enrolled in the study could undergo enteral and/or parenteral nutrition according to the clinical judgement and guidelines in the field
Dhaliwal	2004	Type: Systematic Review/ Meta-Analysis
Doig	2013	Intervention: only 40% of patients received EN Control: only 40.8% never received PN
Dvorak	2004	Intervention: no PN
Elke	2013	Secondary analysis, patients were divided into groups according to the types of nutrition used in the VISEP trial
Fan	2016	Type: Pseudo-randomized
Fetterplace	2019	Intervention: PN only used in case of feeding intolerance (2 patients in standard care group)
Fuentes Padilla	2019	Type: Systematic Review
Harvey	2014	Intervention: exlucsive PN, 6.8% crossover
Ibrahim	2002	Intervention: no PN used, Methodology: no true randomization
Kott	2019	Type: Review
Lewis	2018	Type: Systematic Review/ Meta-Analysis
Luo	2012	Article could not be obtained. Working group of meta-analysis mentioning this study was contacted June 2020, no response

Luo	2020	Type: Systematic Review/ Meta-Analysis
Mazaherpur	2016	Intervention: in the combination group, PN started at a mean of 15 days
Petros	2016	Intervention/ Control: hypocaloric vs. eucaloric, EN, PN and EN+PN used in both groups
Radpay	2016	Control group: total PN, no EN-only group
Schilling	1996	Fulltext not obtained
Shi	2018	Type: Systematic Review/ Meta-Analysis
Singer	2011	Intervention: though significantly more calories were given via PN in the intervention group, 34/56 patients received EN only. Comparison: PN was received by 8/56 patients
Wan	2015	Type: Systematic Review/ Meta-Analysis
Wernerman	2008	Type: Review
Wischmeyer	2012	Type: Editorial
Wu	2017	Patients: 0% mortality, ICU and mechanical ventilation not reported
Xi	2014	Full text could not be obtained, authors were contacted in May 2020 and June 2020 without response